

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092216 A1

(51) International Patent Classification⁷: **C07K 14/705**,
C12N 15/12, 15/85, 15/86, 15/62, 5/10, A61K 38/17,
48/00, A61P 35/00

(74) Agents: **MARTIN, Jean-Jacques** et al.; Cabinet Regim-
beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(21) International Application Number:
PCT/IB2004/001472

(22) International Filing Date: 15 April 2004 (15.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03360049.5 15 April 2003 (15.04.2003) EP

(71) Applicant (for all designated States except US):
TRANGENE S.A. [FR/FR]; 11 rue de Molsheim,
F-67000 Strasbourg (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WAHREN, Britta**
[SE/SE]; Microbiology and Tumorbiology Center,
Karolinska Institute, Swedish Institute for Infectious Dis-
ease Control, Tomtebodavägen 12B, S-171 82 Stockholm
(SE). **WINBERG, Gösta** [SE/SE]; Karolinska Institutet,
Microbiology and Tumorbiology Center, Box 280, Nobels
vag 16, S-171 77 Stockholm (SE). **HINKULA, Jorma**
[SE/SE]; Swedish Institute for Infectious Disease Control,
Tomtebodavägen 12 B, Stockholm (SE). **LUND, Lars**
[US/US]; 601 W 113th St Apt 5d, New York, NY 10025
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **CARCINOEMBRYONIC ANTIGEN (CEA) LACKING A SIGNAL PEPTIDE, NUCLEIC ACID ENCODING IT AND
FUSION OF CEA WITH A T CELL EPITOPE AND THEIR USE FOR THE TREATMENT AND/OR PROPHYLAXIS OF CAN-
CER**

(57) Abstract: The present invention relates to a nucleic acid sequence which encodes a carcino embryonic antigen characterized
in that said nucleic acid sequence does not encode a signal peptide. The present invention also relates to fusion protein comprising
a carcino embryonic antigen and a T cell epitope.

WO 2004/092216 A1

BEST AVAILABLE COPY

ITR004
#12

CARCINOEMBRYONIC ANTIGEN (CEA) LACKING A SIGNAL PEPTIDE, NUCLEIC ACIDS ENCODING IT AND A FUSION OF CEA WITH A T CELL EPITOPE AND THEIR USE FOR THE TREATMENT AND/OR PROPHYLAXIS OF CANCER

The present invention relates to a nucleic acid sequence which encodes a carcino-
5 embryonic antigen characterized in that said nucleic acid sequence does not encode a signal peptide. The present invention also relates to fusion protein comprising a carcino embryonic antigen and a T cell epitope.

The invention also relates to nucleic acid sequence which encodes such fusion
10 proteins, to a vector for expressing the different nucleic acid sequence, to a viral particle and a host cell, and to a composition which comprises them. Finally, the invention is also directed towards their therapeutic use and to a method of treatment which implements them. The present invention is particularly useful, within the context of gene therapy, for an application with respect, to proliferative diseases.

Gene therapy is defined as being the transfer of genetic information into a host cell or
15 organism. The first protocol applied to man was initiated in the United States, in September 1990, on a patient who was genetically immunodeficient on account of a mutation which affected the gene encoding Adenine Deaminase (ADA). The relative success of this first experiment encouraged the development of this approach for a variety of diseases, including both genetic diseases (with the aim of correcting the
20 malfunction of a defective gene) and acquired diseases (cancers, infectious diseases, such as AIDS, etc.). This technology has experienced a large number of developments since then, including cancer vaccination, which uses genes whose expression products are able to induce an immune response directed against tumoral cells antigens, thereby leading to the destruction of such cells.

25 Colon cancer accounts for 10–15% of cancer deaths in the industrialized world, second only to lung cancer. Despite improvements in surgery, chemotherapy and radiotherapy, survival rates are only moderate (40% survive longer than 5 years) and have remained essentially unchanged for the last 20 years. Like many solid tumors, colon cancer may relapse after surgery, probably because of the persistence of
30 micrometastases.

Carcinoembryonic antigen (CEA, also called CEACAM5 3) is a 180 kDa GPI-linked membrane glycoprotein expressed extensively on most human colon, gastric, and

pancreatic carcinomas, as well as on approximately 70% of nonsmall-cell lung carcinomas and 50% of breast cancers. CEA is also expressed on foetal gut tissue and to some extent on normal colonic epithelium.(1,3) It has an approximately 70% homology with nonspecific cross-reacting antigen (NCA), expressed in normal
5 granulocytes.(4) CEA is synthesized as a precursor protein (depicted in SEQ ID NO: 1) with N- and C-terminal signal peptides. These signal peptides target the protein through the endoplasmic reticulum (ER), where it is heavily glycosylated, and subsequently to the cell membrane. Both signal peptides are removed during post-translational processing. The mature protein contains an N-terminal variable region
10 (107 amino acids) and three sets of constant Ig-like repeat regions (178 amino acids each); the C-terminal signal peptide has been replaced by a glycosylphosphatidylinositol (GPI) membrane anchor. The main clinical use of serum CEA has been in postoperative surveillance of colon cancer.

The immunogenicity of endogenous CEA is poor(6,7) Some reports of CEA:anti-CEA
15 complexes in patients exist,(8,9) but others claim that such findings are artefactual. (10,11) Evidence of T-cell responses is scarce, although a response of patient T cells to CEA has been achieved by in vitro immunization with an anti-idiotypic antibody that mimics CEA.(7,12) CEA is expressed extensively on colon carcinomas, and thus constitutes a good potential target for immunotherapy despite its poor
20 immunogenicity. Vaccines using recombinant CEA (rCEA) produced in vaccinia or baculovirus vectors have been used in several studies. Mice immunized with rCEA developed antibody, DTH, lymphoproliferative and cytotoxic responses, and were protected against challenge with murine colon carcinoma cells expressing human CEA.(13) Patients with colon cancer immunized with rCEA mounted a cytotoxic T
25 lymphocyte (CTL) response against tumor cells loaded with CEA peptides.(14) Patients with colon cancer immunized with rCEA mounted both antibody and T-cell responses against CEA that were enhanced by adding granulocyte/macrophage-colony-stimulating factor (GMCSF). (15)

Unlike several infectious diseases, which are well controlled by humoral responses,
30 solid tumors such as colon carcinoma are likely to require cellular responses for effect. Studies in animals reveal that tumor regression is more often associated with cellular than with humoral immunity.(6) While peptide, protein or glycoprotein

vaccines elicit mainly antibody responses, DNA vaccines allow presentation of antigen to the immune system in several ways and have the potential of inducing strong cellular responses. DNA vaccines have been shown to stimulate all three arms of the immune system, that is, antibody, helper T, and cytotoxic T-cell (CTL) responses, (16) to produce immunity in several disease models such as influenza,(17,18) HIV-1,(19,20) and hepatitis B,(21) and to protect animals from subsequent challenge.(18) The mechanisms are considered to involve antigen presentation by both myocytes and antigen-presenting cells (APCs), as well as crosspriming between the two MHC paths. Promising effects have been seen in studies using CEA plasmid DNA vaccines. Humoral, proliferative, and DTH responses were observed in pig-tailed macaques immunized with CEA DNA vaccines,(22) and dogs immunized with CEA DNA vaccines mounted humoral and proliferative responses.(23) Protective effects were also seen in tumor challenge experiments after CEA DNA vaccination in mice . However, there is still a need to improve gene therapy treatment of cancer by CEA DNA vaccination. This problem is solved by the present invention.

The present invention provides new nucleic acid sequences as well as new polypeptides which derive from nucleic acid sequence which encodes CEA. These new sequences and polypeptides induce a more efficient immune response against tumor cells expressing CEA than previously available CEA sequences or polypeptides.

According to a first embodiment, the present invention concerns a nucleic acid sequence which encodes a carcinoembryonic antigen characterized in that said nucleic acid sequence does not encode a signal peptide.

As used herein CEA refers to the Carcinoembryonic antigen, in a preferred embodiment to a protein comprising all or part of an amino acid sequence which is substantially as depicted in SEQ ID NO: 2 and in a more preferred embodiment to an amino acid sequence comprising all or part of an amino acid sequence as depicted in SEQ ID NO: 2. In an even more preferred embodiment, CEA refers to the amino acid sequence depicted in SEQ ID NO: 2.

The term "substantially" refers to a degree of identity with said SEQ ID NO: 2 sequence which is greater than 70%, advantageously greater than 80%, preferably

greater than 90% and, very preferably greater than 95%. Still more preferably, the polypeptide comprises the amino acid sequence depicted in the SEQ ID NO: 2 sequence identifier..

This preferred embodiment can of course be combined with one or more
5 additional mutation(s) at any site in the molecule. Preferably, the additional modification(s) do not significantly affect the antigenicity of the CEA according to the invention. It is pointed out that the antigenicity of the mutants can be tested, in particular using the techniques which are described in the examples which follow.

The term "signal peptide" refers to an amino or carboxy terminal polypeptide
10 preceding the secreted mature protein. The signal peptide is cleaved from and is therefore not present in the mature protein. Signal peptides have the function of directing and translocating secreted proteins across cell membranes. Signal peptide is also referred to as signal protein. For example such signal peptides are depicted in
15 residue Gly in position 678 to residue Ile in position 702.

The present invention also concerns polypeptide encoded by the nucleic acid sequence according to the invention previously described.

In a second embodiment, the present invention concerns a fusion protein comprising a carcinoembryonic antigen and a T cell epitope.

20 A "fusion protein" refers to a chimeric molecule formed by the joining of two or more compounds through a bond formed between one moiety and another moiety. For purposes of this invention, one moiety is a polypeptide. The bond between the polypeptide and the other moiety may be covalent or noncovalent. An example of a covalent bond is the chemical coupling of two polypeptides to form peptide bond.
25 Examples of non-covalent bond are hydrogen bonds, electrostatic interactions and van der Waal's forces.

If the bond is a peptide bond the fusion protein may be expressed as a single polypeptide from a nucleic acid sequence encoding a single contiguous fusion protein. According to a preferred embodiment of the invention, the T cell epitope is
30 linked to the N terminal extremity of the carcinoembryonic antigen.

As used herein the term "T-cell epitope" refers to a feature of a peptide structure which is capable of inducing T-cell immunity towards the peptide structure or

an associated hapten. In this regard, it is accepted in the art that T-cell epitopes comprise linear peptide determinants that assume extended conformations within the peptide-binding cleft of MHC molecules, (Unanue et al., Science (1987) 236:551-557). Conversion of polypeptides to MHC class II-associated linear peptide determinants (generally between 5-14 amino acids in length) is termed "antigen processing" which is carried out by antigen presenting cells (APCs). More particularly, a T-cell epitope is defined by local features of a short peptide structure, such as primary amino acid sequence properties involving charge and hydrophobicity, and certain types of secondary structure, such as helicity, that do not depend on the folding of the entire polypeptide. Further, it is believed that short peptides capable of recognition by helper T-cells are generally amphipathic structures comprising a hydrophobic side (for interaction with the MHC molecule) and a hydrophilic side (for interacting with the T-cell receptor), (Margalit et al., Computer Prediction of T-cell Epitopes, New Generation Vaccines Marcel-Dekker, Inc, ed. G. C. Woodrow et al., (1990) pp. 109-116) and further that the amphipathic structures have an α -helical configuration (see, e.g., Spouge et al., J. Immunol. (1987) 138:204-212; Berkower et al., J. Immunol. (1986) 136:2498-2503).

According to a preferred embodiment, the T cell epitope according to the invention derives from a foreign pathogen. T cell epitopes which derive from foreign pathogens include but are not limited to hepatitis B surface and core antigen helper T cell epitopes), pertussis toxin helper T cell epitopes, tetanus toxoid helper T cell epitopes, measles virus F protein helper T cell epitopes, Chlamydia trachomatis major outer membrane protein helper T cell epitopes, diphtheria toxin helper T cell epitopes, Plasmodium falciparum circumsporozoite helper T cell epitopes, Schistosoma mansoni triose phosphate isomerase helper T cell epitopes, Escherichia coli TraT helper T cell epitopes.

According to a more preferred embodiment, the T cell epitope derives from the tetanus toxoid protein. In an even more preferred embodiment the P2 epitope of the tetanus toxoid protein. In a particularly preferred embodiment the T cell epitope deriving from the P2 epitope of the Tetanus toxoid is substantially as depicted in SEQ ID NO: 3 sequence identifier starting at residue Gln in position 4 and finishing at residue Leu in position 18, and preferably as depicted in SEQ ID NO: 3 sequence

6

identifier starting at residue Gln in position 4 and finishing at residue Leu in position 18.

A preferred fusion protein according to the invention comprises an amino acid sequence which is substantially as depicted in the SEQ ID NO: 3, and more preferably as depicted in the SEQ ID NO: 3. As mentioned above, it can contain additional mutations.

In a general manner, a polypeptide or a fusion protein according to the invention can be produced either by the conventional methods of chemical synthesis or by recombinant DNA techniques (see, for example, Maniatis et al., 1989, Laboratory Manual, Cold Spring Harbor, Laboratory Press, Cold Spring Harbor, NY). For this reason, the present invention also covers a preparation process in which a nucleic acid sequence encoding said polypeptide or fusion protein is introduced into a cell in order to generate a transformed cell, said transformed cell is cultured under conditions appropriate for enabling said polypeptide or said fusion protein to be produced, and said polypeptide or fusion protein is harvested from the cell culture. The producer cell can be of any origin and, without limitation, a bacterium, a yeast or a mammalian cell, to the extent that the nucleic acid sequence under consideration is either integrated into its genome or integrated into, an appropriate expression vector which is able to replicate. Naturally, the nucleic sequence is placed under the control of transcription and translation signals which enable it to be expressed in the producer cell. Expression vectors and control signals are known to the skilled person. The polypeptide can be recovered from the medium or the cells (after they have been lyzed) and subjected to conventional purification steps (by chromatography, electrophoresis, filtration, immunopurification, etc.).

The present invention also relates to a nucleic acid sequence which encodes a fusion protein according to the invention.

According to the invention, the different nucleic acid sequences according to the invention can be a cDNA or genomic sequence or be of a mixed type. It can, where appropriate, contain one or more introns, with these being of native,

heterologous (for example the intron of the rabbit β -globin gene, etc.) or synthetic origin, in order to increase expression in the host cells. The sequences employed within the context of the present invention can be obtained by the conventional techniques of molecular biology, for example by screening libraries with specific probes, by immunoscreening expression libraries or by PCR using suitable primers, or by chemical synthesis. The mutants can be generated from the native sequences by substituting, deleting and/or adding one or more nucleotides using the techniques of site-directed mutagenesis, of PCR, of digesting with restriction and ligation enzymes, or else by chemical synthesis.

10

The present invention also relates to a recombinant vector which carries a nucleic acid sequence according to the invention which is placed under the control of the elements which are required for expressing it in a host cell. The recombinant vector can be of plasmid or viral origin and can, where appropriate, be combined with one or more substances which improve the transfectional efficiency and/or stability of the vector. These substances are widely documented in the literature which is available to the skilled person (see, for example, Feigner et al., 1987, Proc. West. Pharmacol. Soc. 32, 115-121; Hodgson and Solaiman, 1996, Nature Biotechnology 14, 339-342; Remy et al., 1994, Bioconjugate Chemistry, 5, 647-654). By way of non-limiting illustration, the substances can be polymers, lipids, in particular cationic lipids, liposomes, nuclear proteins or neutral lipids. These substances can be used alone or in combination. A combination which can be envisaged is that of a recombinant plasmid vector which is combined with cationic lipids (DOGS, DC-CHOL, spermine-chol, spermidine-chol, etc.), lysophospholipides (for example Hexadecylphosphocholine) and neutral lipids (DOPE).

According to a preferred embodiment, when cationic lipids are used in the present invention, preference will be given to the cationic lipids describes in EP901463B1 and more preferably pcTG90.

The choice of the plasmids which can be used within the context of the present invention is immense. They can be cloning vectors and/or expression vectors. In a general manner, they are known to the skilled person and, while a number of them are available commercially, it is also possible to construct them or to modify

30

them using the techniques of genetic manipulation. Examples which may be mentioned are the plasmids which are derived from pBR322 (Gibco BRL), pUC (Gibco BRL), pBluescript (Stratagene), pREP4, pCEP4 (Invitrogene) or p Poly (Lathe et al., 1987, Gene 57, 193-201). Preferably, a plasmid which is used in the context of
5 the present invention contains an origin of replication which ensures that replication is initiated in a producer cell and/or a host cell (for example, the ColE1 origin will be chosen for a plasmid which is intended to be produced in E. coli and the oriP/EBNA1 system will be chosen if it desired that the plasmid should be self-replicating in a mammalian host cell, Lupton and Levine, 1985, Mol. Cell. Biol. 5, 2533-2542; Yates
10 et al., Nature 313, 812-815). The plasmid can additionally comprise a selection gene which enables the transfected cells to be selected or identified (complementation of an auxotrophic mutation, gene encoding resistance to an antibiotic, etc.). Naturally, the plasmid can contain additional elements which improve its maintenance and/or its stability in a given cell (cer sequence, which promotes maintenance of a plasmid in
15 monomeric form (Summers and Sherrat, 1984, Cell 36, 1097-1103, sequences for integration into the cell genome).

With regard to a viral vector, it is possible to envisage a vector which is derived from a poxvirus (vaccinia virus, in particular MVA, canarypoxvirus, etc.), from
20 an adenovirus, from a retrovirus, from a herpesvirus, from an alphavirus, from a foamy virus or from an adenovirus-associated virus.

According to a preferred embodiment, the viral vector according to the invention derives from a Modified Vaccinia Virus Ankara (MVA). Methods to produce
25 such MVA vectors are fully described in European patents EP83286 and EP206920., and in Mayr et al. (1975, Infection 3, 6-14) and Sutter et Moss (1992, Proc. Natl. Acad. Sci. USA 89, 10847-10851). According to a more preferred embodiment, the nucleic acid sequence according to the invention may be inserted in a deletion selected from the group comprising deletion I, II, III, IV, V and VI of the MVA vector
30 and even more preferably in deletion III (Meyer et al., 1991, J. Gen. Virol. 72, 1031-1038 ; Sutter et al., 1994, Vaccine 12, 1032-1040).

Retroviruses have the property of infecting, and in most cases integrating

into, dividing cells and in this regard are particularly appropriate for use in relation to cancer. A recombinant retrovirus according to the invention generally contains the LTR sequences, an encapsidation region and the nucleic acid sequence according to the invention, which is placed under the control of the retroviral LTR or of an internal promoter such as those described below. The recombinant retrovirus can be derived from a retrovirus of any origin (murine, primate, feline, human, etc.) and in particular from the MOMuLV (Moloney murine leukemia virus), MVS (Murine sarcoma virus) or Friend murine retrovirus (Fb29). It is propagated in an encapsidation cell line which is able to supply in trans the viral polypeptides gag, pol and/or env which are required for constituting a viral particle. Such cell lines are described in the literature (PA317, Psi CRIP GP + Am-12 etc.). The retroviral vector according to the invention can contain modifications, in particular in the LTRs (replacement of the promoter region with a eukaryotic promoter) or the encapsidation region (replacement with a heterologous encapsidation region, for example the VL30 type) (see French applications 94 08300 and 97 05203)

Preference will be also given to using an adenoviral vector which lacks all or part of at least one region which is essential for replication and which is selected from the EI, E2, E4 and L1-L5 regions in order to avoid the vector being propagated within the host organism or the environment. A deletion of the EI region is preferred. However, it can be combined with (an)other modification(s)-/deletion(s) affecting, in particular, all or part of the E2, E4 and/or L1-L5 regions, to the extent that the defective essential functions are complemented in trans by means of a complementing cell line and/or a helper virus. In this respect, it is possible to use second-generation vectors of the state of the art (see, for example, international applications WO-A-94/28152 and WO-A-97/04119). By way of illustration, deletion of the major part of the EI region and of the E4 transcription unit is very particularly advantageous. For the purpose of increasing the cloning capacities, the adenoviral vector can additionally lack all or part of the nonessential E3 region. According to another alternative, it is possible to make use of a minimal adenoviral vector which retains the sequences which are essential for encapsidation, namely the 5' and 3' ITRs (Inverted Terminal Repeat), and the encapsidation region. The various

adenoviral vectors, and the techniques for preparing them, are known (see, for example, Graham and Preveet, 1991, in *Methods in Molecular Biology*, Vol 7, p 109-128; Ed: E.J. Murey, The Human Press mc).

- 5 Furthermore, the origin of the adenoviral vector according to the invention can vary both from the point of view of the species and from the point of view of the serotype. The vector can be derived from the genome of an adenovirus of human or animal (canine, avian, bovine, murine, ovine, porcine, simian, etc.) origin or from a hybrid which comprises adenoviral genome fragments of at least two different origins.
- 10 More particular mention may be made of the CAV-1 or CAV-2 adenoviruses of canine origin, of the DAV adenovirus of avian origin or of the Bad type 3 adenovirus of bovine origin (Zakharchuk et al., *Arch. Virol.*, 1993, 128: 171-176; Spibey and Cavanagh, *J. Gen. Virol.* 1989, 70: 165-172; Jouvenne et al., *Gene*, 1987, 60: 21-28; Mittal et al., *J. Gen. Virol.*, 1995, 76: 93-102). However, preference will be given to an
- 15 adenoviral vector of human origin which is preferably derived from a serotype C adenovirus, in particular a type 2 or 5 serotype C adenovirus.

- An adenoviral vector according to the present invention can be generated in vitro in *Escherichia coli* (*E. coli*) by ligation or homologous recombination (see, for
- 20 example, international application WO-A-96/17070) or else by recombination in a complementing cell line.

- The elements required for expression consist of all the elements which enable the nucleic acid sequence to be transcribed into RNA and the mRNA to be
- 25 translated into polypeptide. These elements comprise, in particular, a promoter which may be regulable or constitutive. Naturally, the promoter is suited to the chosen vector and the host cell. Examples which may be mentioned are the eukaryotic promoters of the PGK (phosphoglycerate kinase), MT (metallothionein; McIvor et al., 1987, *Mol. Cell Biol.* 7, 838-848), α -1_{antitrypsin}, CFTR, surfactant, immunoglobulin,
- 30 β -actin (Tabin et al., 1982, *Mol. Cell Biol.* 2, 426-436) and SRa (Takebe et al., 1988, *Mol. Cell Biol.* 8, 466-472) genes, the early promoter of the SV40 virus (Simian virus), the LTR of RSV (Rous sarcoma virus), the HSV-1 TK promoter, the early promoter of

the CMV virus (Cytomegalovirus), the p7.5K pH5R, pK1L, p28 and p11 promoters of the vaccinia virus, and the E1A and MLP adenoviral promoters. The promoter can also be a promoter which stimulates expression in a tumor or cancer cell. Particular mention may be made of the promoters of the MUC-I gene, which is overexpressed in breast and prostate cancers (Chen et al., 1995, J. Clin. Invest. 96, 2775-2782), of the CEA (standing for carcinoma embryonic antigen) gene, which is overexpressed in colon cancers (Schrewe et al., 1990, Mol. Cell. Biol. 10, 2738-2748) of the tyrosinase gene, which is overexpressed in melanomas (Vile et al., 1993, Cancer Res. 53, 3860-3864), of the ERBB-2 gene, which is overexpressed in breast and pancreatic cancers (Harris et al., 1994, Gene Therapy 1, 170-175) and of the α -fetoprotein gene, which is overexpressed in liver cancers (Kanai et al., 1997, Cancer Res. 57, 461-465). The cytomegalovirus (CMV) early promoter and the is very particularly preferred.

When a vector deriving from a Vaccinia Virus (as for example MVA vector) is used, the promoter of the thymidine kinase 7.5K gene is particularly preferred.

The necessary elements can furthermore include additional elements which improve the expression of the nucleic acid sequence according to the invention or its maintenance in the host cell. Intron sequences, secretion signal sequences, nuclear localization sequences, internal sites for the reinitiation of translation of IRES type, transcription termination poly A sequences, tripartite leaders and origins of replication may in particular be mentioned. These elements are known to the skilled person.

The recombinant vector according to the invention can also comprise one or more additional genes of interest, with it being possible for these genes to be placed under the control of the same regulatory elements (polycistronic cassette) or of independent elements. Genes which may in particular be mentioned are the genes encoding interleukins IL-2, IL-4, IL-7, IL-10 and IL-12, interferons, tumor necrosis factor (TNF), colony stimulating factors (CSF), in particular GM-CSF, and factors acting on angiogenesis (for example PAI-1, standing for plasminogen activator inhibitor). In one particular embodiment, the recombinant vector according to the invention comprises the gene of interest encoding IL-2 or encoding interferon γ (INF γ).

The present invention also relates to a viral particle which comprises a recombinant vector according to the invention. Such a viral particle can be generated from a viral vector using any technique which is conventional in the field of the art. The viral particle is propagated in a complementing cell which is suited to the deficiencies of the vector. With regard to an adenoviral vector, use will, for example, be made of the 293 cell line, which was established using human embryonic kidney cells and which efficiently complements the EI function (Graham et al., 1977, J. Gen. Virol. 36, 59-72), of the A549-E1 cell line (Imler et al., 1996, Gene Therapy 3, 75-84) or of a cell line which permits double complementation (Yeh et al., 1996, J. Virol. 70, 559-565; Krougliak and Graham, 1995, Human Gene Therapy 6, 1575-1586; Wang et al., 1995 Gene Therapy 2, 775-783; international application WO 97/04119). It is also possible to employ helper viruses to at least partially complement the defective functions. A complementing cell is understood as being a cell which is able to supply in trans the early and/or late factors which are required for encapsidating the viral genome in a viral capsid in order to generate a viral particle which contains the recombinant vector. Said cell may not be able to complement all the defective functions of the vector on its own and, in this case, can be transfected/transduced with a vector/helper virus which supplies the additional functions.

The invention also relates to a process for preparing a viral particle, in which process:

- (i) a recombinant vector according to the invention is introduced into a complementing cell which is able to complement said vector in trans, so as to obtain a transfected complementing cell,
- (ii) said transfected complementing cell is cultured under conditions which are appropriate for enabling said viral particle to be produced, and
- (iii) said viral particle is recovered from the cell culture.

While the viral particle can of course be recovered from the culture supernatant, it can also be recovered from the cells. One of the commonly employed methods consists in lysing the cells by means of consecutive freezing/thawing cycles in order to collect the virions in the lysis supernatant. The virions can then be
5 amplified and purified using the techniques of the art (chromatographic method, method of ultra- centrifugation, in particular through a cesium chloride gradient, etc.).

The present invention also relates to a host cell which comprises a nucleic acid sequence or a recombinant vector according to the invention, or is infected with
10 a viral particle according to the invention. For the purposes of the present invention, a host cell consists of any cell which can be transfected with a recombinant vector or can be infected with a viral particle, as defined above. A mammalian cell, in particular a human cell is very particularly suitable. The cell can comprise said vector in a form which is or is not (episome) integrated into the genome. The cell can be a primary or
15 tumor cell of any origin, in particular an hematopoietic cell (totipotent stem cell, leukocyte, lymphocyte, monocyte or macrophage, etc.), muscle cell (satellite cell, myocyte, myoblast, smooth muscle cell, etc.), cardiac cell, pulmonary cell, tracheal cell, hepatic cell, epithelial cell or fibroblast.

20 The present invention, also relates to a composition which comprises a polypeptide, a fusion protein, a nucleic acid sequence, a recombinant vector, a viral particle or a host cell according to the invention in combination with a pharmaceutically acceptable excipient

25 The present invention furthermore relates to a composition which comprises a polypeptide or a fusion protein according to the invention and a polypeptide of interest. Of these polypeptides of interest, particular mention may be made of interleukins IL-2, IL-4, IL-7, IL-10 and IL-12, interferons, tumor necrosis
30 factor (TNF), colony stimulating factors (CSF), in particular GM-CSF, and factors acting on angiogenesis (for example. PAI-1, standing for plasminogen activator inhibitor). IL-2 or INF γ are very particularly envisaged.

The composition can also be based on nucleic acid sequences which enable the above polypeptides to be expressed within the host cell. The nucleic acid sequences may be carried by one and the same expression vector or by two
5 independent vectors. Said composition can of course comprise viral particles which are generated from (a) viral vector(s) expressing said nucleic acid sequence(s).

The present invention additionally relates to a composition which
10 comprises a nucleic acid sequence according to the invention and a second nucleic acid sequence of interest which encodes a polypeptide selected from IL-2 and INF γ .

A composition according to the invention is more specifically intended for the preventive or curative treatment of diseases by means of gene therapy and is
15 more specifically aimed at proliferative diseases (cancers, tumors).

A composition according to the invention can be made conventionally with a view to administering it locally, parenterally or by the digestive route. In particular, a therapeutically effective quantity of the therapeutic or prophylactic agent is combined
20 with a pharmaceutically acceptable excipient. It is possible to envisage a large number of routes of administration. Examples which may be mentioned are the intragastric, subcutaneous, intracardiac, intramuscular, intravenous, intraperitoneal, intratumor, intranasal, intrapulmonary and intratracheal routes. In the case of these three latter embodiments, it is advantageous for administration to take place by
25 means of an aerosol or by means of instillation. The administration can take place as a single dose or as a dose which is repeated on one or more occasions after a particular time interval. The appropriate route of administration and dosage vary depending on a variety of parameters, for example the individual, the disease to be treated or the gene(s) of interest to be transferred. The preparations based on viral
30 particles according to the invention can be formulated in the form of doses of between 10^4 and 10^{14} pfu (plaque-forming units), advantageously 10^5 and 10^{13} pfu, preferably 10^6 and 10^{12} pfu. As far as the recombinant vector according to the invention is

15

concerned, it is possible to envisage doses comprising from 0.01 to 100 mg of DNA, preferably from 0.05 to 10 mg, very particularly preferably from 0.5 to 5 mg. A composition based on polypeptides preferably comprises from 0.05 to 10 g, very particularly preferably from 0.05 to 5 g, of said polypeptide. Naturally, the doses can
5 be adjusted by the clinician.

The composition can also include a diluent, an adjuvant or an excipient which is acceptable from the pharmaceutical point of view, as well as solubilizing, stabilizing and preserving agents. In the case of an injectable administration,
10 preference is given to a composition in an aqueous, non-aqueous or isotonic solution. It can be presented as a single dose or as a multidose, in liquid or dry (powder, lyophilizate, etc.) form which can be reconstituted at the time of use using an appropriate diluent.

15 The present invention also relates to the therapeutic or prophylactic use of a polypeptide, a nucleic acid sequence, a fusion protein, of a recombinant vector, of a viral particle or of a host cell according to the invention for preparing a medicament which is intended for treating the human or animal body by gene therapy or by administering protein which has been produced by the recombinant route. A preferred
20 use consists in treating or preventing cancers, tumors and diseases which result from unwanted cell proliferation. Conceivable applications which may be mentioned are cancers of the breast, of the uterus, of the prostate, of the lung, of the bladder, of the liver, of the colon, of the pancreas, of the stomach, of the esophagus, of the larynx, of the central nervous system and of the blood (lymphomas, leukemia, etc.).

25

Examples

Methods

CEA DNA constructs

30 . The plasmid p91023(B) was a kind gift from Nicole Beauchemin and Clifford Stanners, McGill University, Montreal, Canada. It is a 7385 kb plasmid derived from pBR322. It encodes a full-length clone of human CEA (CEA) (accession number

M17303), driven by the adenovirus major late promoter and with an SV40 poly A tail. CEA is 3036 bp long. p91023(B) contains a 5' untranslated region (UTR) (bp 1–96), a 5' signal sequence (ss) (bp 97–198), the CEA region of interest to us, that is, Δ CEA (bp 199–2121), a 30 ss (bp 2121–2205), and a 30 UTR (bp 2206–3036). It contains tetracycline resistance for selection. PCR primers were designed to amplify the CEA gene excluding the signal sequences. To the 5' end of the sense strand primer were added an EcoRI site and a consensus eukaryotic ribosomal binding site. The codon for leu 36 was changed from CTC to CTT to generate a unique HindIII site. To the 5' end of the antisense primer was added a stop codon and a Sall restriction site for subcloning. The PCR product was cloned into the pGEM T-Easy vector (Promega, Madison, WI). The correct product was verified by DNA sequencing (ABI Prism, Perkin-Elmer, Norwalk, CT) and the DCEA insert was recloned into pKCMV using the Sall and EcoRI sites. The pKCMV vector is constructed from pUC8, containing the CMV promoter, but the open reading frame (ORF) of the β -lactamase gene of this plasmid has been replaced by the ORF of the Tn5 aminoglycoside 3'-phosphotransferase (kanamycin resistance gene) in compliance with the Swedish regulatory standards for DNA vaccines administered to humans. The correct product was verified and named pKCMV Δ CEA. Paired oligonucleotides encoding the promiscuous helper T-cell epitope QYIKANSKFIGITEL (representing amino acids 830–844 of tetanus toxoid) with HindIII sites at both ends were obtained (Life Technologies), annealed and cloned into the HindIII site of pKCMV Δ CEA, thus creating the new sequence MKLQYIKANSKFIGITEL, replacing the original Nterminal signal sequence of CEA. The correct product was verified by DNA sequencing and named pKCEA66.

25

Immunofluorescence staining and immunoblot analysis of CEA expression in transfected cells

HeLa cells were cultured on coverslips in six-well plates (Nunc, Denmark) in IMDM medium (Life Technologies, Rockville, MD) with 1% l-glutamine, 5% FCS and penicillin/streptomycin (penicillin 50 IU/ml and streptomycin 50 mg/ml, Life Technologies) at 37°C until the cells were 60–80% confluent. For transfections, 5 mg of plasmid DNA was mixed with 5 ml 20% glucose and 2.4 ml polyethyleneimine

(Sigma-Aldrich, St Louis, MO) in 20 ml water and added to 1ml of growth medium before adding to the cells. After transfection, the cells were incubated overnight and the medium was changed. At 36– 40 hours post-transfection, the cells on coverslips were washed three times in PBS and then blow-dried before they were fixed on the cover glass with -20°C acetone–methanol (80:20). The cells were immunostained by a standard double antibody technique using a monkey anti-CEA IgG diluted 1/2000 as primary antibody and a fluorescein-conjugated, affinity purified goat anti-human IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) as secondary antibody, diluted 1/50 in PBS with 0.01% Tween-20 and 10% NGS. Finally, the cells were counterstained for 5 minutes with a 1/2000 dilution of Hoechst 33258 (500 mg/ml in water). For testing expression of the plasmid DNAs in immunoblots, D17 canine osteosarcoma or human 293 cells were transfected in 60mm Petri dishes with 9 mg of p91023(B) (wtCEA), the Δ CEA clones or the pKCMV vector control plasmid using 30 ml Lipofectin (Life- Technologies) in DMEM without serum or antibiotics. After 7 hours later, the medium was exchanged for DMEM with 10 % FBS. At 2 days after transfection, the cells were lysed in SDS and analyzed on immunoblots using standard methods, using the monkey-anti-CEA IgG as primary antibody and a horseradish peroxidaseconjugated goat anti-human IgG for detection using a luminol reagent (Amersham-Pharmacia Biotech, UK).

20

Quantitation of CEA expression in LS174T tumor cells using an enzyme-linked immunosorbent assay (ELISA)

The growth medium from a 3-day culture of LS174T cells was centrifuged at 12,000 rpm for 15 minutes to remove cell debris and the supernatant was stored at -20°C until use. The cells were counted, washed three times in PBS, and lysed for 30 minutes on ice in RIPA buffer. Growth medium, cell lysate and rCEA (baculovirus expressed recombinant human CEA protein, Protein Science, Meriden, CT) were then serially diluted with PBS containing 0.5% BSA, 2% normal goat serum (NGS) and 0.05% Tween-20, and preincubated for 1 hour at 37°C with monkey-anti-CEA antibodies (SIIDC, Stockholm) diluted at a final concentration of 1/16,000. A 96- well Nunc ImmunoMaxisorb plate was coated with 0.1 mg/well of rCEA antigen diluted in 0.05M Na₂CO₃ pH 9.6 overnight at room temperature. The wells were washed four

times with 0.9% NaCl, 0.05% Tween-20, blocked 2 hours at 37°C with 2% BSA in PBS and then washed four times. The monkey-anti-CEA antibodies, preincubated with appropriate dilutions of growth medium, cell lysate and rCEA, as described above, were added to different wells and incubated for 2 hours at 37°C. The wells
5 were washed four times before the addition of goat-anti-human IgG diluted 1/3000 in PBS with 0.5% BSA, 2% NGS and 0.05% Tween-20. The plate was incubated for 2 hours at 37°C. After washing the wells four times, the plate was incubated for 15 minutes at 37°C with phosphatase substrate (Sigma Diagnostics Inc.) diluted according to the manufacturer's instructions. The reaction was stopped by adding 1M
10 NaOH and the plate was read at 405 and 650nm in a double-beam ELISA reader. Unspecific binding of monkey-anti-CEA to the plate and goat-antihuman IgG to the antigen were tested as negative controls. Noninhibited monkey-anti-CEA diluted 1/16,000 was used as a positive control. CEA expression in cell lysates as well as in the supernatant medium was normalized to the number of cells in the original culture.
15 CEA expression on the tumor cells and in the medium was calculated using a standard inhibition curve created by incubating known amounts of rCEA with monkey anti-CEA IgG.

Immunization of C57BL/6 mice with CEA plasmids

20 Three groups of ten 10–12-week-old C57BL/6 (H2b) mice were subjected to immunization with plasmid DNA as described below. Plasmid DNAs were transformed into *E. coli* DH5 α (Life Technologies), and purified using Qiagen endotoxin-free Maxi or Mega plasmid preparation kits (Qiagen, Germany) and dissolved at 2 mg/ml in water. One group was immunized intramuscularly (i.m.) in the quadriceps muscle with
25 100 mg of plasmid pKCEA66, one with 100 mg i.m. of plasmid p91023(B) and 10 with 100 mg i.m. of plasmid pKCMV. After 28 days the mice received a second dose of 100 mg of the respective DNAs, administered in the same way. On day 69 the mice in each group received gene gun immunization (see below) with a total of 5 mg of the respective DNAs administered epidermally at two different locations on the abdomen.
30 Blood samples were taken on days 45 and 88 and before the mice were killed on day 103. Sera were used for tests of humoral immune responses by ELISA while spleen

cells were used for testing T-cell and cytokine responses and for transplantation to SCID mice prior to tumor challenge.

Preparation of DNA-loaded gold beads for gene-gun immunization

5 Aliquots of 20.7, 20.4 and 21.7 mg gold beads (Microcarrier 1.0 mm, Bio-Rad Laboratories) were placed in three 1.5 ml microcentrifuge tubes. The pKCEA66, p91023(B) and pKCMV plasmids were added at a loading rate of 5.07, 5.15 and 4.84 mg DNA/mg gold, respectively. Each aliquot, containing approximately 2.5 mg DNA, was prepared for injection by standard techniques and was administered using a
10 helium pulsed Accell device (Geniva Inc., Middletown, WI).

ELISA measurement of isotype-specific antibody responses after immunization of C57BL/6 mice

Coating of 96-well Nunc ImmunoMaxisorb plates was performed overnight at room
15 temperature with with 0.1 mg/well of rCEA antigen (rCEA2) diluted in 0.05M Na₂CO₃ pH 9.6. The wells were washed four times with 0.9% NaCl, 0.05% Tween-20 and then blocked for 2 hours at 37°C with 2% bovine serum albumin (BSA) in PBS. After four washes, serum samples were applied, diluted 1/50 and 1/250 in Buffer A (0.5% BSA and 0.05% Tween-20 in PBS), and incubated for 2 hours at 37°C followed by four
20 washes. Goat anti-mouse IgG1, IgG2a, IgG2b, IgG3 or IgA (Caltag) diluted 1/1000 in Buffer A was added and the plates were incubated 90 minutes at 37°C. After washing the wells four times the plates were incubated 90 minutes at 37°C with alkaline phosphatase conjugated Affinipure rabbit-anti-goat Ig (DAKO) diluted 1/2000 in Buffer A. The wells were washed four times before OPD substrate (o-phenylenediamine
25 dihydrochloride, Sigma, St Louis, MO) diluted in citratephosphate buffer pH 5.0 and H₂O₂ (one tablet in 10 ml buffer and 3 ml H₂O₂) was added and the plates were incubated 20 minutes at room temperature. The reaction was stopped with 2.5M H₂SO₄ and read at 490 and 650nm in a double-beam ELISA reader. Unspecific binding of the anti-mouse antibodies to the antigen was tested as a control. Monkey-
30 anti-CEA IgG and a known positive serum were used as positive controls. To reveal monkey-anti-CEA binding, a 1/20,000 dilution of an affinity-purified goat-anti-human Ig horseradish peroxidase conjugate (BioRad) was used.

Dose titration of human CEA-expressing LS174T cells for tumor challenge experiments

The CEA secreting human colorectal cancer cell line LS174T was grown at 37°C in
5 Parker 199 medium (SBL Vaccin AB, Stockholm, Sweden) with l-glutamine (Life Technologies Ltd), 10% fetal calf serum (FCS) and penicillin/streptomycin (Life Technologies Ltd). To determine the cell dose for subsequent tumor cell challenges a titration with different concentrations of LS174T tumor cells was performed in 10 SCID mice (scid/scid C.B.-17). The mice were divided in two groups and inoculated subcutaneously with three doses of tumor cells each. Five mice received 10^3 , 10^4 and 10^5 cells at different sites and five mice received 10^5 , 10^6 and 3×10^6 cells. Based on this titration, each SCID mouse received challenge doses of 10^6 , 5×10^5 and 10^5 LS174T cells subcutaneously at three separate locations 1 day after receiving an intraperitoneal graft of B-, T-, or B+T-cell-depleted spleen cells from C57BL/6 mice
15 previously immunized with DNA constructs expressing either wtCEA (p91023(B)), tetΔCEA (pKCEA66) or control plasmid (pKCMV).

Negative selection of immune C57BL/6 spleen cells for SCID transplantation

The C57BL/6 mice were killed on day 103 and blood samples and spleens were
20 collected. Spleens were mashed in 5–10 ml medium with 10% FCS. Cell suspensions were centrifuged briefly to remove large cell aggregates, and the supernatants were centrifuged a second time. Cells were resuspended in 5ml medium with 10% FCS, counted, and diluted to 2×10^6 cells per ml. T-cell proliferation tests were made on a small portion of the cells. Spleen cells from each group of mice immunized with the
25 same plasmid were pooled and divided into three equal aliquots for negative selection of effector cells using Dynabeads (Dynal AS, Oslo, Norway). In the first aliquot, B cells were removed using B220 antibody-coated beads, in the second aliquot CD4+ and CD8+ cells (TH and TC cells) were removed using L3T4 and Lyt2 antibody-coated beads and in the third aliquot both B cells, CD4+ and CD8+ cells were removed using
30 a combination of all three beads. The antibodies for coating were rat antimouse monoclonal antibodies. The cell separation was performed according to the manufacturer's protocols. Controls of cell depletion efficacy by FACS revealed that

92–97% of the targeted cells had been removed. Following removal of the magnetic beads, the cell suspension was concentrated to a proper volume and injected intraperitoneally (i.p.) in SCID mice. Within each group of 10 SCID mice, three mice received spleen cells depleted for B cells, three mice received spleen cells depleted for T cells and four mice received T- and B-cell-depleted cells. Within the group receiving spleen cells from pKCEA66- immunized C57BL/6, the spleen cell numbers were as follows: B-cell depleted, $30.8 \cdot 10^6$ cells per mouse; T-cell depleted, $64.8 \cdot 10^6$ cells per mouse; B- and T-cell depleted, $19.1 \cdot 10^6$ cells per mouse. Within the group receiving spleen cells from p91023(B) (wtCEA)-immunized C57BL/6, the spleen cell numbers were as follows: B-cell depleted, $24.4 \cdot 10^6$ cells per mouse; T-cell depleted, $44.3 \cdot 10^6$ cells per mouse; B- and T-cell depleted, $14.4 \cdot 10^6$ cells per mouse. Within the group receiving spleen cells from pKCMV (vector)-immunized C57BL/6, the spleen cell numbers were as follows: B-cell depleted, $55.6 \cdot 10^6$ cells per mouse; T-cell depleted, $53.6 \cdot 10^6$ cells per mouse; B- and T-cell depleted, $15.8 \cdot 10^6$ cells per mouse. A fourth group of SCID mice received no spleen cell transplants. The day after the spleen cells had been injected, the SCID mice were inoculated with LS174T tumor cells subcutaneously in three doses: 10^6 , $5 \cdot 10^5$ and 10^5 cells at different sites and the tumor size was measured on days 4, 7, 12 and 15 after tumor challenge. SCID mice were killed on day 15 when the maximum permissible tumor size was reached; however, SCID mice in the group receiving spleen cells from C57BL/6 mice immunized with pKCEA66 were monitored for tumor growth up to 4 weeks.

T-cell stimulation assays

All media used in immunoassays consisted of RPMI 1640 containing 5 or 10% heat-inactivated FCS, 1% penicillin/ streptomycin (final concentration 50 IU/ml and 50 mg/ml, respectively) (Life Technologies), 0.2mM 2-mercaptoethanol, and 10mM sodium pyruvate, unless otherwise noted. Spleen cells from the immunized C57BL/6 mice were cultured in RPMI medium with 10% FCS. The following components were added to 96-well plates in 100 μ l medium with 10% FCS: medium alone, ConA (final concentration 5 mg/ml), native CEA (10 mg/ml) and rCEA (10 mg/ml), or recombinant control protein (rCP, 10 mg/ml). Subsequently, $2 \cdot 10^5$ cells per well in another 100 μ l medium with 10% FCS was added. Each sample was made in triplicate. Cells were

cultured at 37°C for 5 days. ³H-labelled thymidine (50 µl per well, 1 mCi) was added and the cells were incubated for another 16 hours before they were harvested in a Harvester 96 (Tomtec, CT) and the incorporation of thymidine by the cells was measured in a liquid β-scintillation counter (Wallac Micro Beta TriluxTM, Turku, Finland). The SI was calculated by dividing the mean cpm values from the triplicate CEA stimulated wells with the mean cpm of the medium control wells.

Results

Wild-type and mutated CEA show different intracellular expression patterns

The DNAs tested for expression in D17 or 293 cells were wtCEA represented by p91023(B), ΔCEA with deleted signal sequences (pKCMVΔCEA) and pKCEA66, where the promiscuous helper T cell epitope QYIKANSKFIGITEL (representing amino acids 830–844 of tetanus toxoid) was inserted at the N terminus of the CEA in pKCMVΔCEA and one clone of a negative vector control (pKCMV). The wtCEA protein, expressed from the p91023(B) plasmid, shows a characteristic expression pattern of a plasma membrane protein, i.e. presence in the ruffled edge and cytoplasmic projections of the cell. In contrast, the majority of the ΔCEA protein was found in aggregates in a perinuclear or cytoplasmic distribution, while only a minority of the ΔCEA protein was observed on the membrane. CEA protein expressed from the pKCEA66 vector gave rise to a homogeneous cytoplasmic fluorescence with marked vacuolization. The pKCMV vector was negative. Cell lysates from transfected cells were analyzed on immunoblots. rCEA protein was used as a positive control and migrated at 130–200 kDa; ΔCEA migrated at 130 kDa, while wtCEA (p91023(B)) had bands both at 130 and 200 kDa. rCEA purified from a baculovirus expression system is differently glycosylated and has a size of 120 kDa with considerable size variation on immunoblots. Eliminating the signal sequences also eliminates glycosylation (since the protein is not translocated to the ER). p91023(B) encodes full-length CEA, which is glycosylated, although overexpression and aberrant intracellular transport in the transfected cells may limit glycosylation of some full-length CEA molecules, explaining the appearance of two bands.

Humoral immune responses in C57BL/6 mice immunized with the pKCEA66 plasmid favor IgG1 over IgG2a.

Humoral immune responses after plasmid DNA immunizations were tested by ELISA for CEA reactive antibodies of isotypes IgG1, IgG2a, IgG2b, IgG3, IgM and IgA.

5 IgG2b-specific responses were similar to IgG2a. The IgG3, IgM and IgA responses were low and did not differ significantly between the groups of immunized mice. The response profiles were carried out with sera collected at the time of killing, on day 103. The antibodies were directed against both native and rCEA. All mice immunized with plasmid pKCEA66 had a strong IgG1 response. The IgG1 response was stronger
10 than any of the other subclasses. Three of 10 mice immunized with plasmid p91023(B) also developed strong IgG1 responses, while none of the mice immunized with the empty plasmid pKCMV had a significant humoral response. The immunization schedule was as described in Methods. These results show that CEA specific humoral immune responses were raised against the wtCEA plasmid
15 p91023(B) as well as against the pKCEA66 plasmid.

C57BL/6 mice immunized with plasmids encoding wtCEA or tet Δ CEA (tetanus toxoid P2 epitope/CEA fusion protein encoded pKCEA66) by mount T-cell-specific responses to CEA

20 Proliferation of lymphocytes in response to CEA antigen following plasmid immunization was analyzed in parallel with the humoral response. A small portion of pooled spleen cells collected from each group of immunized C57BL/6 mice was used for T-cell proliferation assays. Mice immunized with plasmid pKCEA66 developed a cell-mediated response with a mean SI of 6.2. Spleen cells from mice immunized with
25 plasmid p91023(B) had a mean SI of 4.0 and spleen cells from mice immunized with plasmid pKCMV showed no significant reactivity to CEA (SI of 1.2). A SI above 2 was considered positive. Spleen cells from the group immunized with pKCEA66 showed higher activity.

30 Spleen cells from pKCEA66-immunized C57BL/6 mice reduce both tumor frequency and tumor growth rate in SCID mice after challenge with CEA tumor cells

Spleen cells from the plasmid-immunized C57BL/6 mice were transplanted to SCID mice intraperitoneally, after a negative selection had been performed where B, T or both B and T cells were removed. The SCID mice were then inoculated with human tumor cells in three doses and the tumor growth was measured. The control SCID animals received tumor cells only. The LS174T tumor cells expressed 0.22 pg CEA/cell and secreted 0.41 pg CEA/cell into the medium during 3 days. This indicates a continuous and high expression and secretion of CEA antigen by the cells. The tumor take frequency as well as tumor growth differed significantly ($P < 0.01$) between animals receiving spleen cells from pKCEA66-immunized C57BL/6 mice, and animals in all other groups. In the group receiving pKCEA66-immunized spleen cells, only four of 10 animals developed tumors at all, and only in the highest tumor cell dose (10^6 tumor cells). The growth rate and final size of these tumors in the individuals receiving spleen cells from pKCEA66-immunized mice was also strongly diminished. In groups of SCID mice receiving spleen cells from C57BL/6 mice immunized with p91023(B) or the pKCMV vector control, all the tumor take rates were similar and did not differ significantly from the tumors of SCID mice receiving no spleen cells.

References :

1. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. *J Exp Med.* 1965;122:467–481.
3. Beauchemin N, Draber P, Dveksler G, et al. Redefined nomenclature for members of the carcinoembryonic family. *Exp Cell Res.* 1999;252:243–249.
4. Wahren B, Gadler F, Gahrton G, et al. NCA: a differentiation antigen of myelopoietic cells in humans and hominoid monkeys. *Ann NY Acad Sci.* 1983;417:344–358.
6. Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Colorectal cancer vaccines. *Br J Surg.* 1998;85:149–154.
7. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotypic antibody vaccine. *J Clin Invest.* 1995;96:334–342.
8. Mavligit GM, Stuckey S. Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes. *Cancer.* 1983;52:146–149.

9. Staab HJ, Anderer FA, Stumpf E, Fischer R. Are circulating CEA immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract? *Br J Cancer*. 1980;42:26–33.
10. Chester KA, Begent RH. Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer. *Clin Exp Immunol*. 1984;58:685–693.
11. Collatz E, Von Kleist S, Burtin P. Further investigations of circulating antibodies in colon cancer patients: on the utoantigenicity of the carcinoembryonic antigen. *Int J Cancer*. 1971;8:298–303.
- 10 12. Durrant LG, Denton GW, Jacobs E, et al. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours. *Int J Cancer*. 1992;50:811–816.
13. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. *J Natl Cancer Inst*. 1992;84: 1084–1091.
- 15 14. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine [see comments]. *J Natl Cancer Inst*. 1995;87:982–990.
- 20 15. Samanci A, Yi Q, Fagerberg J, et al. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. *Cancer Immunol Immunother*. 1998;47:131–142.
- 25 16. Cohen AD, Boyer JD, Weiner DB. Modulating the immune response to genetic immunization. *Faseb J*. 1998;12: 1611–1626. by parenteral, mucosal, and gene- gun inoculations. *Proc Natl Acad Sci USA*. 1993;90:11478–11482.
18. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. *Science*. 1993;259:1745–1749.
- 30 19. Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. *Proc Natl Acad Sci USA*. 1993;90:4156– 4160.

20. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1- infected patients. *Lancet*. 1998;351:1320–1325. 21. Davis HL, Michel ML, Mancini M, Schleef M, Whalen RG.
21. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against
5 the hepatitis B virus surface antigen. *Vaccine*. 1994;12:1503–1509.
22. Conry RM, White SA, Fultz PN, et al. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. *Clin Cancer Res*. 1998;4:2903–2912.
23. Smith BF, Baker HJ, Curiel DT, Jiang W, Conry RM. Humoral and cellular
immune responses of dogs immunized with a nucleic acid vaccine encoding human
10 carcinoembryonic antigen. *Gene Therapy*. 1998;5:865–868.

Claims

- 5 1. A nucleic acid sequence which encodes a carcinoembryonic antigen characterized in that said nucleic acid sequence does not encode a signal peptide.
- 10 2. A nucleic acid sequence according to claim 1, wherein said carcinoembryonic antigen comprises an amino acid sequence substantially as depicted in SEQ ID NO: 2
3. A nucleic acid sequence according to claim 1, wherein said carcinoembryonic antigen comprises an amino acid sequence as depicted in SEQ ID NO: 2.
- 15 4. A polypeptide encoded by the nucleic acid sequence according to anyone of claims 1 to 3.
- 20 5. A fusion protein comprising:
 - a polypeptide according to claim 4 and
 - a T cell epitope.
- 25 6. A fusion protein according to claim 5, wherein the T cell epitope is linked to the N terminal extremity of said polypeptide.
7. A fusion protein according to claim 5, wherein the T cell epitope derives from the tetanus toxoid protein.
- 30 8. A fusion protein according to claim 7, wherein the T cell epitope derives from the P2 epitope of the tetanus toxoid protein.
- 35 9. A fusion protein according to claim 8, wherein the T cell epitope comprises a amino acid sequence substantially as depicted in SEQ ID NO: 3 sequence identifier starting at residue Gln in position 4 and finishing at residue Leu in position 18.
10. A fusion protein according to claim 9, wherein the T cell epitope comprises an

amino acid sequence as depicted in SEQ ID NO: 3 sequence identifier starting at residue Gln in position 4 and finishing at residue Leu in position 18.

- 5 11. A nucleic acid sequence which encodes a fusion protein according to one of claims 5 to 10.
- 10 12. A recombinant vector which carries a nucleic acid sequence according to claim 11 or to one of claims 1 to 3 placed under the control of the elements which are required for expressing it in a host cell.
- 15 13. A recombinant vector according to claim 12, characterized in that said vector is selected from the group consisting of the plasmid and viral vectors, where appropriate combined with one or more substances which improve(s) the transfectional efficacy and/or the stability of the vector.
- 20 14. A recombinant vector according to claim 13, wherein said substance which improve the transfectional efficacy and/or the stability of the vector is selected from the group consisting in cationic lipids, cationic polymers, lysophospholipides and polypeptides.
- 25 15. A recombinant vector according to Claim 13, characterized in that said vector is a viral vector which is derived from a pox virus, from an adenovirus, from a retrovirus, from a herpes virus, from an alphavirus, from a foamyvirus or from an adenovirusassociated virus.
- 30 16. A recombinant vector according to claim 15, characterized in that said vector derived from a Modified Vaccinia Ankara (MVA) virus.
- 35 17. A recombinant vector according to claim 16, characterized in that the nucleic acid sequence according to claim 11 or to anyone of claims 1 to 3 is inserted at a site of a naturally occurring deletion within the MVA genome selected from the group consisting in deletion I, II, III, IV, V and VI.
18. A recombinant vector according to claim 17, wherein the site of the naturally occurring deletion is deletion III.

19. A recombinant vector according to one of claims 12 to 18, characterized in that the elements which are required for the expression comprising a promoter.
- 5 20. A recombinant vector according to claims 17 or 18, characterized in that the promoter is the promoter of the thymidine kinase 7.5K gene.
- 10 21. A recombinant vector according to claim 15, characterized in that said vector is an adenoviral vector which lacks all or part of at least one region which is essential for replication and which is selected from the EI, E2, E4 and L1-L5 regions.
- 15 22. A recombinant vector according to Claim 21, characterized in that said vector is an adenoviral vector which additionally lacks all or part of the non-essential E3 region.
- 20 23. A recombinant vector according to claim 12, characterized in that the elements which are required for the expression comprise a promoter, in particular the cytomegalovirus (CMV) early promoter.
- 25 24. A recombinant vector according to one of claims 12 to 24, characterized in that it additionally comprises one or more genes of interest which is/are selected from the genes encoding interleukins IL-2, IL-4, IL-7, IL-10 and IL-12, interferons, tumor necrosis factor (TNF), colony stimulating factors (CSF) and factors acting on angiogenesis.
- 30 25. A recombinant vector according to claim 24, characterized in that the gene of interest encodes a polypeptide which is selected from IL-2 and INF γ .
- 35 26. A process for preparing a viral particle, in which:
a recombinant vector according to one of claims 15 to 25 is introduced into a complementing cell which is able to complement said vector in trans so as to obtain a transfected complementing cell;
said transfected complementing cell is cultured under conditions which are appropriate for enabling said viral particle to be produced, and
said viral particle is recovered from the cell culture.
27. A viral particle which comprises a recombinant vector according to one of

claims 15 to 25 or was obtained in accordance with the process according to claim 26.

- 5 28. A host cell which comprises a nucleic acid sequence according to one of claims 1 to 3, or a nucleic acid sequence according to claim 11, or a recombinant vector according to one of claims 12 to 25, or which is infected with a viral particle according to claim 27.
- 10 29. A composition which comprises a polypeptide according to claim 4, a fusion protein according to one of claims 5 to 10, a nucleic acid sequence according to one of claims 1 to 3, a nucleic acid sequence according to claim 11, a recombinant vector according to one of claims 12 to 25, a viral particle according to claim 27, or a host cell according to claim 28, in combination with a pharmaceutically acceptable excipient.
- 15 30. Therapeutic or prophylactic use of a polypeptide according to claim 4, a fusion protein according to one of claims 5 to 10, a nucleic acid sequence according to one of claims 1 to 3, a nucleic acid sequence according to claim 11, a recombinant vector according to one of claims 12 to 25, a viral particle according to claim 27, or a host cell according to claim 28 for preparing a medicament which is intended for treating the human or animal body by gene therapy or by administering protein which has been produced by the recombinant route.
- 20 31. Use according to claim 30, for preparing a medicament which is intended for treating cancers, tumors and diseases which result from unwanted cell proliferation.
- 25 32. Process for preparing a polypeptide according to claim 4, a fusion protein according to one of claims 5 to 10, in which:
a nucleic acid sequence according to one of claims 1 to 3, or a nucleic acid sequence according to claim 11 is introduced into a cell in order to generate a transformed cell
said transformed cell is cultured under conditions which are appropriate for enabling said polypeptide to be produced, and
30 said polypeptide or said fusion protein is harvested from the cell culture.
- 35

SEQUENCE LISTING

<110> TRANSGENE SA

<120> Nucleic acid sequences, polypeptides and fusion protein
deriving from Carcinoembryonic antigen (CEA)

<130> D21232

<150> EP 03/360 049

<151> 2003-04-15

<160> 3

<170> PatentIn Ver. 2.1

<210> 1

<211> 702

<212> PRT

<213> Homo sapiens

<400> 1

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Ser | Pro | Ser | Ala | Pro | Pro | His | Arg | Trp | Cys | Ile | Pro | Trp | Gln |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Leu | Leu | Leu | Thr | Ala | Ser | Leu | Leu | Thr | Phe | Trp | Asn | Pro | Pro | Thr |
| | | | 20 | | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ala | Lys | Leu | Thr | Ile | Glu | Ser | Thr | Pro | Phe | Asn | Val | Ala | Glu | Gly |
| | | 35 | | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Glu | Val | Leu | Leu | Leu | Val | His | Asn | Leu | Pro | Gln | His | Leu | Phe | Gly |
| | 50 | | | | | 55 | | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | Ser | Trp | Tyr | Lys | Gly | Glu | Arg | Val | Asp | Gly | Asn | Arg | Gln | Ile | Ile |
| 65 | | | | | 70 | | | | | 75 | | | | 80 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Tyr | Val | Ile | Gly | Thr | Gln | Gln | Ala | Thr | Pro | Gly | Pro | Ala | Tyr | Ser |
| | | | 85 | | | | | | 90 | | | | | 95 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Arg | Glu | Ile | Ile | Tyr | Pro | Asn | Ala | Ser | Leu | Leu | Ile | Gln | Asn | Ile |
| | | | 100 | | | | | 105 | | | | | 110 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Gln | Asn | Asp | Thr | Gly | Phe | Tyr | Thr | Leu | His | Val | Ile | Lys | Ser | Asp |
| | | 115 | | | | | 120 | | | | | 125 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Val | Asn | Glu | Glu | Ala | Thr | Gly | Gln | Phe | Arg | Val | Tyr | Pro | Glu | Leu |
| | 130 | | | | | 135 | | | | | 140 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Lys | Pro | Ser | Ile | Ser | Ser | Asn | Asn | Ser | Lys | Pro | Val | Glu | Asp | Lys |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Ala | Val | Ala | Phe | Thr | Cys | Glu | Pro | Glu | Thr | Gln | Asp | Ala | Thr | Tyr |
| | | | 165 | | | | | | 170 | | | | | 175 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Trp | Trp | Val | Asn | Asn | Gln | Ser | Leu | Pro | Val | Ser | Pro | Arg | Leu | Gln |
| | | | 180 | | | | | 185 | | | | | 190 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ser | Asn | Gly | Asn | Arg | Thr | Leu | Thr | Leu | Phe | Asn | Val | Thr | Arg | Asn |
| | | 195 | | | | | 200 | | | | | 205 | | | |

Asp Thr Ala Ser Tyr Lys Cys Glu Thr Gln Asn Pro Val Ser Ala Arg
 210 215 220
 Arg Ser Asp Ser Val Ile Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro
 225 230 235 240
 Thr Ile Ser Pro Leu Asn Thr Ser Tyr Arg Ser Gly Glu Asn Leu Asn
 245 250 255
 Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser Trp Phe
 260 265 270
 Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn
 275 280 285
 Ile Thr Val Asn Asn Ser Gly Ser Tyr Thr Cys Gln Ala His Asn Ser
 290 295 300
 Asp Thr Gly Leu Asn Arg Thr Thr Val Thr Thr Ile Thr Val Tyr Ala
 305 310 315 320
 Glu Pro Pro Lys Pro Phe Ile Thr Ser Asn Asn Ser Asn Pro Val Glu
 325 330 335
 Asp Glu Asp Ala Val Ala Leu Thr Cys Glu Pro Glu Ile Gln Asn Thr
 340 345 350
 Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg
 355 360 365
 Leu Gln Leu Ser Asn Asp Asn Arg Thr Leu Thr Leu Leu Ser Val Thr
 370 375 380
 Arg Asn Asp Val Gly Pro Tyr Glu Cys Gly Ile Gln Asn Glu Leu Ser
 385 390 395 400
 Val Asp His Ser Asp Pro Val Ile Leu Asn Val Leu Tyr Gly Pro Asp
 405 410 415
 Asp Pro Thr Ile Ser Pro Ser Tyr Thr Tyr Tyr Arg Pro Gly Val Asn
 420 425 430
 Leu Ser Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser
 435 440 445
 Trp Leu Ile Asp Gly Asn Ile Gln Gln His Thr Gln Glu Leu Phe Ile
 450 455 460
 Ser Asn Ile Thr Glu Lys Asn Ser Gly Leu Tyr Thr Cys Gln Ala Asn
 465 470 475 480
 Asn Ser Ala Ser Gly His Ser Arg Thr Thr Val Lys Thr Ile Thr Val
 485 490 495
 Ser Ala Glu Leu Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro
 500 505 510
 Val Glu Asp Lys Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Ala Gln
 515 520 525
 Asn Thr Thr Tyr Leu Trp Trp Val Asn Gly Gln Ser Leu Pro Val Ser

| 530 | 535 | 540 |
|--|-----|-----|
| Pro Arg Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn 545 550 555 560 | | |
| Val Thr Arg Asn Asp Ala Arg Ala Tyr Val Cys Gly Ile Gln Asn Ser 565 570 575 | | |
| Val Ser Ala Asn Arg Ser Asp Pro Val Thr Leu Asp Val Leu Tyr Gly 580 585 590 | | |
| Pro Asp Thr Pro Ile Ile Ser Pro Pro Asp Ser Ser Tyr Leu Ser Gly 595 600 605 | | |
| Ala Asn Leu Asn Leu Ser Cys His Ser Ala Ser Asn Pro Ser Pro Gln 610 615 620 | | |
| Tyr Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln His Thr Gln Val Leu 625 630 635 640 | | |
| Phe Ile Ala Lys Ile Thr Pro Asn Asn Asn Gly Thr Tyr Ala Cys Phe 645 650 655 | | |
| Val Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Ser Ile 660 665 670 | | |
| Thr Val Ser Ala Ser Gly Thr Ser Pro Gly Leu Ser Ala Gly Ala Thr 675 680 685 | | |
| Val Gly Ile Met Ile Gly Val Leu Val Gly Val Ala Leu Ile 690 695 700 | | |

<210> 2

<211> 644

<212> PRT

<213> Homo sapiens

<400> 2

| |
|--|
| Met Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly Lys 1 5 10 15 |
| Glu Val Leu Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly Tyr 20 25 30 |
| Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Ile Gly 35 40 45 |
| Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Tyr Ser Gly 50 55 60 |
| Arg Glu Ile Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Ile Ile 65 70 75 80 |
| Gln Asn Asp Thr Gly Phe Tyr Thr Leu His Val Ile Lys Ser Asp Leu 85 90 95 |
| Val Asn Glu Glu Ala Thr Gly Gln Phe Arg Val Tyr Pro Glu Leu Pro 100 105 110 |
| Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro Val Glu Asp Lys Asp |

| 115 | | | | | 120 | | | | | 125 | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Ala | Val | Ala | Phe | Thr | Cys | Glu | Pro | Glu | Thr | Gln | Asp | Ala | Thr | Tyr | Leu | |
| 130 | | | | | 135 | | | | | 140 | | | | | | |
| Trp | Trp | Val | Asn | Asn | Gln | Ser | Leu | Pro | Val | Ser | Pro | Arg | Leu | Gln | Leu | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| Ser | Asn | Gly | Asn | Arg | Thr | Leu | Thr | Leu | Phe | Asn | Val | Thr | Arg | Asn | Asp | |
| 165 | | | | | 170 | | | | | 175 | | | | | | |
| Thr | Ala | Ser | Tyr | Lys | Cys | Glu | Thr | Gln | Asn | Pro | Val | Ser | Ala | Arg | Arg | |
| 180 | | | | | 185 | | | | | 190 | | | | | | |
| Ser | Asp | Ser | Val | Ile | Leu | Asn | Val | Leu | Tyr | Gly | Pro | Asp | Ala | Pro | Thr | |
| 195 | | | | | 200 | | | | | 205 | | | | | | |
| Ile | Ser | Pro | Leu | Asn | Thr | Ser | Tyr | Arg | Ser | Gly | Glu | Asn | Leu | Asn | Leu | |
| 210 | | | | | 215 | | | | | 220 | | | | | | |
| Ser | Cys | His | Ala | Ala | Ser | Asn | Pro | Pro | Ala | Gln | Tyr | Ser | Trp | Phe | Val | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | |
| Asn | Gly | Thr | Phe | Gln | Gln | Ser | Thr | Gln | Glu | Leu | Phe | Ile | Pro | Asn | Ile | |
| 245 | | | | | 250 | | | | | 255 | | | | | | |
| Thr | Val | Asn | Asn | Ser | Gly | Ser | Tyr | Thr | Cys | Gln | Ala | His | Asn | Ser | Asp | |
| 260 | | | | | 265 | | | | | 270 | | | | | | |
| Thr | Gly | Leu | Asn | Arg | Thr | Thr | Val | Thr | Thr | Ile | Thr | Val | Tyr | Ala | Glu | |
| 275 | | | | | 280 | | | | | 285 | | | | | | |
| Pro | Pro | Lys | Pro | Phe | Ile | Thr | Ser | Asn | Asn | Ser | Asn | Pro | Val | Glu | Asp | |
| 290 | | | | | 295 | | | | | 300 | | | | | | |
| Glu | Asp | Ala | Val | Ala | Leu | Thr | Cys | Glu | Pro | Glu | Ile | Gln | Asn | Thr | Thr | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | |
| Tyr | Leu | Trp | Trp | Val | Asn | Asn | Gln | Ser | Leu | Pro | Val | Ser | Pro | Arg | Leu | |
| 325 | | | | | 330 | | | | | 335 | | | | | | |
| Gln | Leu | Ser | Asn | Asp | Asn | Arg | Thr | Leu | Thr | Leu | Leu | Ser | Val | Thr | Arg | |
| 340 | | | | | 345 | | | | | 350 | | | | | | |
| Asn | Asp | Val | Gly | Pro | Tyr | Glu | Cys | Gly | Ile | Gln | Asn | Glu | Leu | Ser | Val | |
| 355 | | | | | 360 | | | | | 365 | | | | | | |
| Asp | His | Ser | Asp | Pro | Val | Ile | Leu | Asn | Val | Leu | Tyr | Gly | Pro | Asp | Asp | |
| 370 | | | | | 375 | | | | | 380 | | | | | | |
| Pro | Thr | Ile | Ser | Pro | Ser | Tyr | Thr | Tyr | Tyr | Arg | Pro | Gly | Val | Asn | Leu | |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 | |
| Ser | Leu | Ser | Cys | His | Ala | Ala | Ser | Asn | Pro | Pro | Ala | Gln | Tyr | Ser | Trp | |
| 405 | | | | | 410 | | | | | 415 | | | | | | |
| Leu | Ile | Asp | Gly | Asn | Ile | Gln | Gln | His | Thr | Gln | Glu | Leu | Phe | Ile | Ser | |
| 420 | | | | | 425 | | | | | 430 | | | | | | |
| Asn | Ile | Thr | Glu | Lys | Asn | Ser | Gly | Leu | Tyr | Thr | Cys | Gln | Ala | Asn | Asn | |
| 435 | | | | | 440 | | | | | 445 | | | | | | |

Ser Ala Ser Gly His Ser Arg Thr Thr Val Lys Thr Ile Thr Val Ser
 450 455 460
 Ala Glu Leu Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro Val
 465 470 475 480
 Glu Asp Lys Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Ala Gln Asn
 485 490 495
 Thr Thr Tyr Leu Trp Trp Val Asn Gly Gln Ser Leu Pro Val Ser Pro
 500 505 510
 Arg Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn Val
 515 520 525
 Thr Arg Asn Asp Ala Arg Ala Tyr Val Cys Gly Ile Gln Asn Ser Val
 530 535 540
 Ser Ala Asn Arg Ser Asp Pro Val Thr Leu Asp Val Leu Tyr Gly Pro
 545 550 555 560
 Asp Thr Pro Ile Ile Ser Pro Pro Asp Ser Ser Tyr Leu Ser Gly Ala
 565 570 575
 Asn Leu Asn Leu Ser Cys His Ser Ala Ser Asn Pro Ser Pro Gln Tyr
 580 585 590
 Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln His Thr Gln Val Leu Phe
 595 600 605
 Ile Ala Lys Ile Thr Pro Asn Asn Asn Gly Thr Tyr Ala Cys Phe Val
 610 615 620
 Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Ser Ile Thr
 625 630 635 640
 Val Ser Ala Ser

<210> 3

<211> 661

<212> PRT

<213> Artificial sequence

<220>

<223> Description of artificial sequence: fusion
 protein between tetanus toxoid 830-844 T cell
 epitope and CEA

<400> 3

Met Lys Leu Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr
 1 5 10 15

Glu Leu Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly
 20 25 30

Lys Glu Val Leu Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly
 35 40 45

Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Ile
 50 55 60
 Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Tyr Ser
 65 70 75 80
 Gly Arg Glu Ile Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Ile
 85 90 95
 Ile Gln Asn Asp Thr Gly Phe Tyr Thr Leu His Val Ile Lys Ser Asp
 100 105 110
 Leu Val Asn Glu Glu Ala Thr Gly Gln Phe Arg Val Tyr Pro Glu Leu
 115 120 125
 Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro Val Glu Asp Lys
 130 135 140
 Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Thr Gln Asp Ala Thr Tyr
 145 150 155 160
 Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg Leu Gln
 165 170 175
 Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn Val Thr Arg Asn
 180 185 190
 Asp Thr Ala Ser Tyr Lys Cys Glu Thr Gln Asn Pro Val Ser Ala Arg
 195 200 205
 Arg Ser Asp Ser Val Ile Leu Asn Val Leu Tyr Gly Pro Asp Ala Pro
 210 215 220
 Thr Ile Ser Pro Leu Asn Thr Ser Tyr Arg Ser Gly Glu Asn Leu Asn
 225 230 235 240
 Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser Trp Phe
 245 250 255
 Val Asn Gly Thr Phe Gln Gln Ser Thr Gln Glu Leu Phe Ile Pro Asn
 260 265 270
 Ile Thr Val Asn Asn Ser Gly Ser Tyr Thr Cys Gln Ala His Asn Ser
 275 280 285
 Asp Thr Gly Leu Asn Arg Thr Thr Val Thr Thr Ile Thr Val Tyr Ala
 290 295 300
 Glu Pro Pro Lys Pro Phe Ile Thr Ser Asn Asn Ser Asn Pro Val Glu
 305 310 315 320
 Asp Glu Asp Ala Val Ala Leu Thr Cys Glu Pro Glu Ile Gln Asn Thr
 325 330 335
 Thr Tyr Leu Trp Trp Val Asn Asn Gln Ser Leu Pro Val Ser Pro Arg
 340 345 350
 Leu Gln Leu Ser Asn Asp Asn Arg Thr Leu Thr Leu Leu Ser Val Thr
 355 360 365
 Arg Asn Asp Val Gly Pro Tyr Glu Cys Gly Ile Gln Asn Glu Leu Ser

| 370 | 375 | 380 |
|--|-----|-----|
| Val Asp His Ser Asp Pro Val Ile Leu Asn Val Leu Tyr Gly Pro Asp 385 390 395 400 | | |
| Asp Pro Thr Ile Ser Pro Ser Tyr Thr Tyr Tyr Arg Pro Gly Val Asn 405 410 415 | | |
| Leu Ser Leu Ser Cys His Ala Ala Ser Asn Pro Pro Ala Gln Tyr Ser 420 425 430 | | |
| Trp Leu Ile Asp Gly Asn Ile Gln Gln His Thr Gln Glu Leu Phe Ile 435 440 445 | | |
| Ser Asn Ile Thr Glu Lys Asn Ser Gly Leu Tyr Thr Cys Gln Ala Asn 450 455 460 | | |
| Asn Ser Ala Ser Gly His Ser Arg Thr Thr Val Lys Thr Ile Thr Val 465 470 475 480 | | |
| Ser Ala Glu Leu Pro Lys Pro Ser Ile Ser Ser Asn Asn Ser Lys Pro 485 490 495 | | |
| Val Glu Asp Lys Asp Ala Val Ala Phe Thr Cys Glu Pro Glu Ala Gln 500 505 510 | | |
| Asn Thr Thr Tyr Leu Trp Trp Val Asn Gly Gln Ser Leu Pro Val Ser 515 520 525 | | |
| Pro Arg Leu Gln Leu Ser Asn Gly Asn Arg Thr Leu Thr Leu Phe Asn 530 535 540 | | |
| Val Thr Arg Asn Asp Ala Arg Ala Tyr Val Cys Gly Ile Gln Asn Ser 545 550 555 560 | | |
| Val Ser Ala Asn Arg Ser Asp Pro Val Thr Leu Asp Val Leu Tyr Gly 565 570 575 | | |
| Pro Asp Thr Pro Ile Ile Ser Pro Pro Asp Ser Ser Tyr Leu Ser Gly 580 585 590 | | |
| Ala Asn Leu Asn Leu Ser Cys His Ser Ala Ser Asn Pro Ser Pro Gln 595 600 605 | | |
| Tyr Ser Trp Arg Ile Asn Gly Ile Pro Gln Gln His Thr Gln Val Leu 610 615 620 | | |
| Phe Ile Ala Lys Ile Thr Pro Asn Asn Asn Gly Thr Tyr Ala Cys Phe 625 630 635 640 | | |
| Val Ser Asn Leu Ala Thr Gly Arg Asn Asn Ser Ile Val Lys Ser Ile 645 650 655 | | |
| Thr Val Ser Ala Ser 660 | | |

| | | | | | |
|--|---|--|---|--|------------------------------|
| A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/705 C12N15/12 C12N15/85 C12N15/86 C12N15/62 C12N5/10 A61K38/17 A61K48/00 A61P35/00 | | | | | |
| According to International Patent Classification (IPC) or to both national classification and IPC | | | | | |
| B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N A61K A61P | | | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | | | | |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE, SCISEARCH, WPI Data, PAJ | | | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | | | |
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | | | | Relevant to claim No. |
| X | WO 95/32286 A (MICROGENESYS INC) 30 November 1995 (1995-11-30) pages 9,10 pages 19,20 page 15 examples 4,7 | | | | 1-4, 12, 13, 19, 26-32 |
| X | WO 02/40059 A (LOUKINOV DMITRI I ; MINCHEFF MILCHO S (US); ZOUBAK SEQUEI (US); AMERIC) 23 May 2002 (2002-05-23) page 35 example 7 | | | | 1-4, 19, 23, 29-31 |
| Y | page 41 - page 56 <div style="text-align: center;">----- -/-</div> | | | | 15-32 |
| <div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div> | | | | | |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents :</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*&* document member of the same patent family</p> </div> </div> | | | | | |
| Date of the actual completion of the international search <div style="text-align: center;">19 August 2004</div> | | | Date of mailing of the international search report <div style="text-align: center;">06/09/2004</div> | | |
| Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | | | Authorized officer <div style="text-align: center;">Domingues, H</div> | | |

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-------------------------------|
| Category * | Citation of documents, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | <p>US 5 672 513 A (TERSIKH ALEXEY ET AL) 30 September 1997 (1997-09-30)</p> <p>column 6 columns 8,9</p> | 1-4,12, 13,19, 23,28,32 |
| Y | <p>SLINGLUFF C L JR ET AL: "Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. OCT 2001, vol. 7, no. 10, October 2001 (2001-10), pages 3012-3024, XP002293206 ISSN: 1078-0432 pages 3102-3 page 3019 page 3020 page 3022 table 5</p> | 5-32 |
| Y | <p>GAL LE F-A ET AL: "Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 98, no. 2, 2002, pages 221-227, XP002225276 ISSN: 0020-7136 the whole document</p> | 5-32 |
| Y | <p>US 4 603 112 A (PAOLETTI ENZO ET AL) 29 July 1986 (1986-07-29) the whole document</p> | 15-32 |
| Y | <p>MOINGEON P: "Cancer vaccines" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 11-12, 8 December 2001 (2001-12-08), pages 1305-1326, XP004313943 ISSN: 0264-410X the whole document</p> | 1-32 |
| Y | <p>EP 0 346 710 A (MOLECULAR DIAGNOSTICS INC) 20 December 1989 (1989-12-20) the whole document</p> | 1-32 |

| Patent document cited in search report | | Publication date | Patent fam. member(s) | | Publication date |
|---|---|---------------------|--|--|--|
| WO 9532286 | A | 30-11-1995 | AU WO | 2517995 A 9532286 A2 | 18-12-1995 30-11-1995 |
| WO 0240059 | A | 23-05-2002 | AU WO | 3944102 A 0240059 A2 | 27-05-2002 23-05-2002 |
| US 5672513 | A | 30-09-1997 | CA EP JP | 2116640 A1 0618292 A1 6321992 A | 26-09-1994 05-10-1994 22-11-1994 |
| US 4603112 | A | 29-07-1986 | US AT AU AU DE DK DK EP IL IT JP JP JP NZ PH US US US US US US US US US US US US IT US US US ZA | 4769330 A 50791 T 561816 B2 9180682 A 3280128 D1 109497 A 572482 A 0083286 A2 67537 A 1165451 B 1941428 C 6071429 B 58129971 A 202833 A 22658 A 6267965 B1 5482713 A 5583028 A 6340462 B1 5972597 A 6183750 B1 5338683 A 5174993 A 4722848 A 5378457 A 2003064077 A1 5505941 A 1191150 B 5942235 A 5110587 A 8209386 A | 06-09-1988 15-03-1990 21-05-1987 30-06-1983 12-04-1990 24-09-1997 25-06-1983 06-07-1983 28-02-1986 22-04-1987 23-06-1995 14-09-1994 03-08-1983 14-03-1986 14-11-1988 31-07-2001 09-01-1996 10-12-1996 22-01-2002 26-10-1999 06-02-2001 16-08-1994 29-12-1992 02-02-1988 03-01-1995 03-04-2003 09-04-1996 24-02-1988 24-08-1999 05-05-1992 28-09-1983 |
| EP 0346710 | A | 20-12-1989 | US AT AU AU DE DE DK EP ES FI IE IL JP NO NZ US | 5122599 A 97162 T 628348 B2 3644389 A 68910590 D1 68910590 T2 296189 A 0346710 A2 2059621 T3 892910 A 62161 B1 90594 A 2107190 A 892220 A 229514 A 6342583 B1 | 16-06-1992 15-11-1993 17-09-1992 21-12-1989 16-12-1993 17-03-1994 17-12-1989 20-12-1989 16-11-1994 17-12-1989 28-12-1994 20-11-1997 19-04-1990 18-12-1989 28-05-1991 29-01-2002 |

| Patent document (cited in search report) | Publication date | Patent family members | Publication date |
|--|------------------|-----------------------|------------------|
| EP 0346710 | A | US 6013772 A | 11-01-2000 |
| | | US 6022958 A | 08-02-2000 |
| | | ZA 8904553 A | 28-03-1990 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.